Exiting the EU: our work to ensure the best deal for cancer research and patients

Brexit & the EU

Get in touch

To request a meeting or further information about our work please contact the Public Affairs team.

Email us

Following the British public’s decision to leave the European Union, we’ll be working hard to help inform negotiations, ensuring cancer patients in the UK and across the EU are prioritised in Brexit talks.

Health and science are global. And collaboration between the UK and countries in Europe and beyond enables the discoveries that benefit patients everywhere. So we’ll be following progress on the UK’s new relationship with the EU closely and seeking to input our expertise on the issues we care most about.

As the largest independent funder of research in Europe we remain committed to collaborating across borders within Europe, and globally, to beat cancer sooner.

Scientists have greater impact when they collaborate internationally.

A report funded by eight leading UK medical research funders and charities identifies some of the main ways in which UK research contributes to medical progress. It highlights the benefit this has delivered for EU science, and ultimately how this has improved the health of patients across the EU.

Related documents

Cancer Research UK briefing for Westminster Hall debate on clinical trials (May 2019)

Cancer Research UK European Election briefing for prospective UK MEPs (May 2019)

Cancer Research UK response to MHRA consultation on EU exit no-deal proposals (November 2018)

Cancer Research UK’s response to the MHRA No Deal consultation (November 2018)

Impact of a no deal Brexit - Cancer Research UK submission to Health and Social Care Committee inquiry (October 2018)

CRUK Policy Position: Summary of Brexit priorities (September 2018)

Cancer Research UK briefing - European regulatory system for medicines (September 2018)

Cancer Research UK’s policy statement on clinical trials as the UK exits the EU (August 2018)

The Future of Clinical Trials After Brexit report (August 2018)

The Future of Clinical Trials After Brexit slide deck (August 2018)

Response to the House of Commons Science and Technology Committee (June 2018)

Cancer charity joint letter: Priorities for second phase Brexit negotiations

CRUK policy position: Clinical Trials Regulation

CRUK Policy position: Drug licensing

CRUK Policy position: Researcher mobility (May 2018)

Campaign for us

Rate this page:

Currently rated: 2.9 out of 5 based on 12 votes
Thank you!
We've recently made some changes to the site, tell us what you think